Clinical Trial: NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

U.S., May 9 -- ClinicalTrials.gov registry received information related to the study (NCT06963021) titled 'NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)' on April 30.

Brief Summary: The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.

Study Start Date: May, 2025

Study Type: INTERVENTIONAL

Condition: Major Depressive Disorder

Intervention: DRUG: NBI-1065845

NBI-1065845 tablets

DRUG: Placebo

Matching placebo tablets

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Neurocrine Biosciences

Published by HT Digital Cont...